Indoco Remedies · NSE: INDOCO · BSE: 532612
Q2 FY22 results · Jul–Sep 2021
Indoco Remedies reported revenue from operations of ₹386.87 crore (up 17.9% from Q2 FY21) and net profit of ₹41.69 crore (up 62.5% from Q2 FY21) for Q2 FY22 (Jul–Sep 2021), on a consolidated basis.
| Item | Q2 FY22 | Q2 FY21 | YoY | Q1 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 386.87 | 328.24 | +17.9% | 386.75 | +0.0% |
| Other income | 1.01 | 0.52 | +94.2% | 0.86 | +17.4% |
| Total income | 387.88 | 328.76 | +18.0% | 387.61 | +0.1% |
| Profit before tax | 64.95 | 36.78 | +76.6% | 61.29 | +6.0% |
| Net profit for the period | 41.69 | 25.65 | +62.5% | 39.66 | +5.1% |
| EPS, basic (₹) | 4.52 | 2.78 | +62.6% | 4.30 | +5.1% |
| Net margin (%) | 10.8 | 7.8 | 10.3 |
| Item | Q2 FY22 | Q2 FY21 | YoY | Q1 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 386.59 | 327.65 | +18.0% | 386.49 | +0.0% |
| Other income | 1.01 | 0.52 | +94.2% | 0.86 | +17.4% |
| Total income | 387.60 | 328.17 | +18.1% | 387.35 | +0.1% |
| Profit before tax | 64.81 | 36.24 | +78.8% | 61.21 | +5.9% |
| Net profit for the period | 41.57 | 25.11 | +65.6% | 39.61 | +4.9% |
| EPS, basic (₹) | 4.51 | 2.72 | +65.8% | 4.30 | +4.9% |
| Net margin (%) | 10.8 | 7.7 | 10.2 |
Consolidated
- Filed with BSE
- 02 Nov 2021, 17:34 IST
- Board meeting
- 02 Nov 2021
- Period
- 01 Jul 2021 to 30 Sep 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 02 Nov 2021, 17:34 IST
- Board meeting
- 02 Nov 2021
- Period
- 01 Jul 2021 to 30 Sep 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE